dr. rule on long-term follow-up of ibrutinib monotherapy in relapsed/refractory mcl
Published 4 years ago • 99 plays • Length 1:36Download video MP4
Download video MP3
Similar videos
-
1:56
dr. goy discusses long-term follow-up results for ibrutinib in mcl
-
1:27
dr. rule on the combination of venetoclax and ibrutinib in mcl
-
3:51
selecting therapy for relapsed/refractory mcl
-
1:09
dr. ritchie on the immunologic impact of long-term venetoclax/ibrutinib in r/r mcl
-
1:24
dr. goy on preliminary data with ibrutinib/venetoclax in relapsed/refractory mcl
-
1:25
dr. lee on early efficacy data with cirmtuzumab/ibrutinib in relapsed/refractory mcl
-
2:39
simon rule, md, discusses the ibrutinib data in relapsed/refractory mcl presented at ash 2017
-
6:11
ibrutinib beats temsirolimus in relapsed/refractory mcl
-
4:40
mcl: long-term safety/efficacy data with ibrutinib
-
1:05
dr. goy on combinations with novel agents in relapsed/refractory mcl
-
1:47
dr. leslie on the role of btk inhibitors in relapsed/refractory mcl
-
1:28
dr. rule on potential for car t-cell therapy in mcl
-
1:35
dr. lee on b-cell receptor targeting in relapsed/refractory mcl
-
1:08
dr. song on zanubrutinib activity in relapsed/refractory mcl
-
1:35
long-term ibrutinib outcomes vs. prior regimens: pooled analysis in r/r mcl
-
0:59
dr. rule on the fda approval of zanubrutinib in mcl
-
1:27
dr. ritchie on immunological response to venetoclax/ibrutinib in r/r mcl
-
0:48
real-world results in the uk for ibrutinib at first relapsed for mcl
-
1:08
dr. gerson on updates in relapsed/refractory mcl